Ablynx aims to launch llama-based arthritis drug in 2013

01/26/2010 | Reuters

Ablynx CEO Edwin Moses said the Belgian company expects to launch its first llama-derived nanomedicine as early as 2013 through a partnership with Pfizer. The drug, which was developed from extra-small antibodies from llamas, could replace Pfizer's Enbrel as a blockbuster treatment for rheumatoid arthritis.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Actuarial Services, Government Programs
PacificSource
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC